ToolGen Incorporated 199800

ToolGen, Inc. (CEO Dr. Jong-Sang Ryu, KOSDAQ: 199800), a pioneer in CRISPR-Cas9 genome-editing technology, announced the successful inauguration of its advanced Genome-Edited Crop Field Testing Facility and the hosting of its Open Innovation Mini-Symposium at the Osong Innovation Circle in Cheongju, South Korea.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global CRISPR-based Gene Editing Market size & share revenue was valued at approximately USD 3.65 Billion in 2024 and is expected to reach USD 4.10 Billion in 2025 and is expected to reach around USD 12.6 Billion by 2034, at a CAGR of 13.01% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are CRISPR Therapeutics A

ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, including lipid nanoparticle (LNP)-based delivery systems. Through this agreement, the companies will jointly advance the development of next-generation in vivo genome-editing therapeutics.

GenEditBio Limited ("GenEditBio"), a Hong Kong-headquartered clinical-stage biotechnology company specializing in novel deliveries, including lipid nanoparticle (LNP)-based delivery systems, announced today that it has entered into a strategic cross-license agreement with ToolGen Inc., a leading genome editing company based in Korea. Through this agreement, the companies will jointly advance the development of next-generation in vivo genome-editing therapeutics.